Cargando…

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

BACKGROUND: Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The objective of this analysis is to report results from study 201 blinded per...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDade, Eric, Cummings, Jeffrey L., Dhadda, Shobha, Swanson, Chad J., Reyderman, Larisa, Kanekiyo, Michio, Koyama, Akihiko, Irizarry, Michael, Kramer, Lynn D., Bateman, Randall J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768996/ https://www.ncbi.nlm.nih.gov/pubmed/36544184 http://dx.doi.org/10.1186/s13195-022-01124-2

Ejemplares similares

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
por: Honig, Lawrence S., et al.
Publicado: (2023)

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
por: Dhadda, Shobha, et al.
Publicado: (2022)

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial
por: Berry, Donald A., et al.
Publicado: (2023)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2021)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2022)

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
por: Hayato, Seiichi, et al.
Publicado: (2022)

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease
por: Satlin, Andrew, et al.
Publicado: (2016)

Reply: Unblinding in the lecanemab trial in Alzheimer’s disease
por: Hardy, John, et al.
Publicado: (2023)

Lecanemab: A hope in the management of Alzheimer’s disease
por: Thakkar, Nandita, et al.
Publicado: (2023)

Lecanemab reduces brain amyloid-β and delays cognitive worsening
por: Knopman, David S.
Publicado: (2023)

Reply: Lecanemab: turning point, or status quo? An ethics perspective
por: Hardy, John, et al.
Publicado: (2023)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
por: Jönsson, Linus, et al.
Publicado: (2023)

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
por: Geerts, Hugo, et al.
Publicado: (2023)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
por: Igarashi, Ataru, et al.
Publicado: (2023)

The informed road map to prevention of Alzheimer Disease: A call to arms
por: McDade, Eric, et al.
Publicado: (2021)

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
por: Verger, Antoine, et al.
Publicado: (2023)

Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
por: Qiao, Yue, et al.
Publicado: (2023)

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
por: Rafii, Michael S., et al.
Publicado: (2023)

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review
por: Chowdhury, Selia, et al.
Publicado: (2023)

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective
por: Volloch, Vladimir, et al.
Publicado: (2023)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Strong Extension-Free Proof Systems
por: Heule, Marijn J. H., et al.
Publicado: (2019)

Legionella and the Prevention of Legionellosis
por: McDade, Joseph E.
Publicado: (2008)

Segue: Brief summaries of articles on pertinent emerging issues published elsewhere.
por: McDade, Joseph E.
Publicado: (2004)

Segue: Brief summaries of articles on pertinent emerging issues published elsewhere.
por: McDade, Joseph E.
Publicado: (2004)

Segue: Brief summaries of articles on pertinent emerging issues published elsewhere.
por: McDade, Joseph E.
Publicado: (2004)

Addressing the potential threat of bioterrorism--value added to an improved public health infrastructure.
por: McDade, J E
Publicado: (1999)

The Microbial Challenge: Human-Microbe Interactions
por: McDade, Joseph E.
Publicado: (2002)

Lecanemab en la enfermedad de Alzheimer: ¿realmente estamos ante un cambio en el pronóstico de la enfermedad?
por: Pérez-Martínez, David A.
Publicado: (2023)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Bioterrorism as a public health threat.
por: McDade, J E, et al.
Publicado: (1998)

A decision theory paradigm for evaluating identifier mapping and filtering methods using data integration
por: Day, Roger S, et al.
Publicado: (2013)

Making sense of estimates of health aid from China
por: McDade, Kaci Kennedy, et al.
Publicado: (2020)

Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2019)

Emerging Infectious Diseases Journal: A Time of Transition
por: McDade, Joseph E., et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_4c1a5havpfek6okk47dua8c2vc